Transgene is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. Transgene has a portfolio of 4 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene has a production site in France.

Employees

145

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
17/07/26	€0.7370	+0.82%	59,288
16/07/26	€0.7310	-1.22%	23,571
15/07/26	€0.7400	-0.54%	23,097
14/07/26	€0.7440	-1.46%	21,152
13/07/26	€0.7550	-0.26%	10,418

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.7370EUR

Average target price

1.100EUR

Spread / Average Target

+49.25%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Euronext Paris Other stock markets 23:55:00 17/07/2026 HKT			5-day change	1st Jan Change
0.7370 ^EUR	+0.82%		-2.64%	-23.23%

06-29	Transgene SA - Special Call
06-25	Oddo BHF Stays Positive on Transgene

Market Cap	202M 231M 186M 172M 324M 22.24B 331M 2.23B 876M 10.89B 867M 848M 37.5B	P/E 2026 *	-5.26x	P/E 2027 *	-3.35x
Enterprise Value	133M 152M 122M 113M 213M 14.62B 217M 1.46B 575M 7.16B 570M 558M 24.65B	EV / Sales 2026 *	18.4x	EV / Sales 2027 *	27x
Free-Float	19.4%	Yield 2026 *	-	Yield 2027 *	-

06-29	Transgene SA - Special Call
06-25	Oddo BHF Stays Positive on Transgene
06-25	Positive Preclinical Data for a Transgene Vaccine
06-25	Transgene Presents Preclinical Data Demonstrating Robust Protection Against Mpox With Its Novel Scalable Cell Line?Derived MVA Vaccine Candidate TG-MVATM	CI
06-22	Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine	CI
06-22	Transgene launches a clinical trial evaluating TG4070 with nivolumab
06-22	Transgene Begins Phase 1 Trial of Non-small Cell Lung Cancer Vaccine	MT
05-22	Transgene SA Announces Board Appointments	CI
04-13	Transgene Completes Patient Randomization in Phase 2 Clinical Trial Evaluating TG4050 in Adjuvant Treatment of Head and Neck Cancer	CI
04-07	Transgene stands out following licensing agreement with NEC Bio
04-03	Transgene, NEC Bio Enter Partnership to Develop Cancer Vaccine	MT
04-03	Transgene and NEC Bio Sign License Agreement for TG4050 Development in Head and Neck Cancer	CI
04-03	Transgene & NEC Bio sign license agreement to prepare next steps of development of TG4050 in head & neck cancer	RE

06-25	Oddo BHF Stays Positive on Transgene
04-07	Transgene stands out following licensing agreement with NEC Bio
11-27	Oddo BHF Lowers Target Price on Transgene but Remains Upbeat
13/10/25	Transgene and BioInvent International AB Jointly Present a Poster on Transational Data and Updated Clinical Results from the Phase I Study of BT-001	CI
19/09/25	Transgene: analysts reiterate their recommendations after results

Transgene Stock

Stocks

TNG

FR0005175080

Biotechnology & Medical Research

Valuation: Transgene

Chart: Transgene

Latest news : Transgene

Last Transcript: Transgene

Analysts' recommendations: Transgene

Press Releases: Transgene

News in other languages: Transgene

Quotes and Performance

Course Extremes

Managers and Directors: Transgene

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise

07-08	Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2026	GL
06-25	Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line–Derived MVA Vaccine Candidate (TG MVA(TM)) at WCID 2026	GL
06-22	Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine	GL
05-26	Transgene : Investor presentation (20260526 Transgene Investor Presentation)	PU
05-26	Transgene to Present Preclinical Data on Novel TG-MVA Prophylactic Vaccine Against mpox at the World Congress on Infectious Diseases	GL

07-08	Transgene : Bilan du Contrat de Liquidité avec la Société Natixis Oddo BHF SCA au 30 juin 2026
07-08	Bilan du Contrat de Liquidité avec la Société Natixis Oddo BHF SCA au 30 juin 2026
06-25	Oddo BHF toujours positif sur Transgene
06-25	Des données précliniques positives pour un vaccin de Transgene
06-25	Bourse : Micron on fire, Volkswagen lâche du lest, Renault réduit la voilure

1 day	+0.82%
1 week	-2.64%
Current month	+1.66%
1 month	-1.99%
3 months	-4.41%
6 months	-22.42%
Current year	-23.23%

1 week	0.73	0.76
1 month	0.72	0.78
Current year	0.72	1.03
1 year	0.72	1.5
3 years	0.53	1.86
5 years	0.53	2.99
10 years	0.53	3.79

Manager	Title	Age	Since
Alessandro Riva CEO	Chief Executive Officer	65	01/06/2023
Lucie Larguier DFI	Director of Finance/CFO	-	27/03/2024
Simone Steiner CTO	Chief Tech/Sci/R&D Officer	-	02/04/2025

Director	Title	Age	Since
Benoît Habert BRD	Director/Board Member	61	27/07/2010
Jean-Luc Bélingard BRD	Director/Board Member	76	19/06/2013
Alain Mérieux BRD	Director/Board Member	88	01/01/2007

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/12/25	Compagnie Merieux Alliance SAS	Buy	Company	38,492,172	28.9953%
2/12/25	Compagnie Merieux Alliance SAS	Buy	Company	84,745,400	63.8367%
2/8/24	Compagnie Merieux Alliance SAS	Buy	Company	30,898,876	23.3562%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TRANSGENE	+0.82%	-2.64%	-5.75%	-60.08%	231M
ARGENX SE	+0.24%	-1.54%	+52.85%	+71.85%	53.83B
WUXI APPTEC CO., LTD.	-7.17%	-4.39%	+42.72%	+73.32%	52.1B
INSMED INCORPORATED	+0.80%	-6.31%	+5.62%	+417.78%	23.48B
BIONTECH SE	-0.09%	-0.01%	-16.85%	-15.41%	23.13B
WUXI BIOLOGICS (CAYMAN) INC.	-5.95%	-2.58%	+29.53%	-9.47%	19.36B
GENMAB A/S	-1.14%	+0.03%	+31.67%	-30.65%	17.56B
PHARMAESSENTIA CORPORATION	-5.16%	-7.00%	+168.44%	+314.96%	15.2B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-6.91%	-5.83%	+25.17%	+644.30%	14.83B
EXELIXIS, INC.	+0.43%	-1.03%	+25.75%	+189.74%	14.06B
Average	-2.41%	-2.63%	+35.91%	+159.63%	23.38B
Weighted average by Cap.	-2.80%	-2.36%	+39.50%	+142.93%

	2026 *	2027 *
Net sales	7.2M 8.24M 6.64M 6.12M 11.54M 793M 11.8M 79.41M 31.23M 389M 30.94M 30.26M 1.34B	7.2M 8.24M 6.64M 6.12M 11.54M 793M 11.8M 79.41M 31.23M 389M 30.94M 30.26M 1.34B
Net income	-38.2M -43.71M -35.25M -32.49M -61.24M -4.21B -62.6M -421M -166M -2.06B -164M -161M -7.1B	-61.6M -70.49M -56.84M -52.39M -98.75M -6.79B -101M -679M -267M -3.32B -265M -259M -11.44B
Net Debt	-69.2M -79.19M -63.86M -58.86M -111M -7.63B -113M -763M -300M -3.73B -297M -291M -12.86B	-7.7M -8.81M -7.11M -6.55M -12.34M -849M -12.62M -84.93M -33.4M -416M -33.09M -32.36M -1.43B